Research and Markets: The Global Anti-Hypertension Market In 2009 at $36.9 Billion, Indicating A Compound Annual Growth Rate (CAGR) Of 5.3% between 2001 And 2009

Research and Markets (http://www.researchandmarkets.com/research/796d56/antihypertension) has announced the addition of GlobalData's new report "Anti-hypertension - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering.

GlobalData, the industry analysis specialist, has released a new report, Anti-hypertension - Drug Pipeline Analysis and Market Forecasts to 2016. The report is an essential source of information and analysis on the global anti-hypertension market. The report identifies the key trends shaping and driving the dynamism in the global anti-hypertension market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global anti-hypertension sector.

The Anti-hypertension Market Is Expected to Witness Steep Decline Due to the Patent Expiry of Blockbusters

GlobalData estimated the global anti-hypertension market in 2009 at $36.9 billion, indicating a compound annual growth rate (CAGR) of 5.3% between 2001 and 2009. The growth in the market can be mainly attributed to the growth in the sales of angiotensin renin blockers (ARB), the only therapeutic class that has antihypertensive drugs under patent protection. Though ARBs are less effective compared to other drugs such as beta-blockers (BBs, also known as beta-adrenergic receptor antagonists) and calcium channel blockers, they became the frontline treatment for patients diagnosed with hypertension. The prevalence of hypertension was another major factor responsible for the growth of anti-hypertension market between 2001 and 2009. Due to expected patent expiry of blockbusters such as Diovan, Cozaar and Avapro, the market is forecast to decline at a CAGR of -5.5% between 2009 and 2016.

The Current Competition in the Anti-hypertension Market Is Very Strong Since There Are Five Therapeutic Classes of Drugs Serving the Market

GlobalData found that the current competition in the anti-hypertension market is very strong. The market in 2009 was dominated by ARBs such as Diovan, Atacand, Blopress and Avapro. In 2009, agents acting on the renin angiotensin system dominated the anti-hypertension market and they accounted for approximately 60% of the market. ARBs alone accounted for 42.6% of the global anti-hypertension market. Among the drugs approved for hypertension, diuretics are the most cost effective drugs. Despite the cost effectiveness and efficacy of diuretics, ARBs and Angiontensin converting enzyme (ACE) inhibitors are the most widely prescribed antihypertensive therapies in the market. In 2009, they accounted for approximately 30% to 40% of the global hypertension prescription volume. BBs were the second leading therapeutic class of drugs, accounting for approximately 30% of the global hypertension prescription volume. Diuretics were the third leading therapeutic class of drugs accounting for approximately 17% of the prescription volume.

Summary

Anti-Hypertension - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global anti-hypertension market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global anti-hypertension market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global anti-hypertension sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.

Scope

The scope of the report includes:

• Annualized global anti-hypertension market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
• Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class drugs act through new mechanisms of action such as eNOS (Endothelial Nitric Oxide Synthase) couplers, sodium-glucose transport 2 (SGLT2) inhibitors, endothelin antagonists, peroxisome proliferator-activated receptor (PPAR)-gamma agonists and cyclooxygenase-1 (COX-1) inhibitors.
• Analysis of the current and future market competition in the global anti-hypertension market. Key future market-players covered are Novartis Ag, Merck & Co. Inc., AstraZeneca, Takeda Pharmaceuticals, Daiichi Sankyo Co. Ltd, GlaxoSmithKline Plc, and Sanofi-Aventis.
• Insightful reviews of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with anti-hypertension.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global anti-hypertension market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global anti-hypertension market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What's the next big thing in the global anti-hypertension market landscape? - Identify, understand and capitalize.

Key Topics Covered:

• 1 Executive Summary
• 2 Anti-hypertension Market: Market Characterization
• 3 Anti-hypertension Market: Competitive Assessment
• 4 Anti-hypertension Market: Pipeline Assessment
• 5 Anti-hypertension Market: Implications for Future Market Competition
• 6 Anti-hypertension Market: Future Players in Anti-hypertension Market
• 7 Anti-hypertension Market: Appendix

Companies Mentioned:

• Novartis AG
• Merck & Co. Inc.
• AstraZeneca
• Daiichi Sankyo Co. Ltd
• Boehringer Ingelheim GmbH
• GlaxoSmithKline
• Sanofi-aventis

For more information visit http://www.researchandmarkets.com/research/796d56/antihypertension